Mesoridazine

Mesoridazine

Systematic (IUPAC) name
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
Clinical data
Trade names	Serentil
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a682306
Pregnancy category	US: C (Risk not ruled out)
Legal status	℞ (Prescription only)
Routes of administration	Oral, intravenous
Pharmacokinetic data
Protein binding	4%
Metabolism	Hepatic/renal
Biological half-life	24 to 48 hours
Excretion	Biliary and renal
Identifiers
CAS Number	5588-33-0 Y
ATC code	N05AC03 (WHO)
PubChem	CID: 4078
IUPHAR/BPS	7227
DrugBank	DB00933 Y
ChemSpider	3936 Y
UNII	5XE4NWM740 Y
KEGG	D02671 Y
ChEBI	CHEBI:6780 Y
ChEMBL	CHEMBL1088 Y
Chemical data
Formula	C21H26N2OS2
Molecular mass	386.576 g/mol
SMILES O=S(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C
InChI InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3 Y Key:SLVMESMUVMCQIY-UHFFFAOYSA-N Y
Physical data
Melting point	130 °C (266 °F)
Solubility in water	insoluble mg/mL (20 °C)
(verify)

Mesoridazine (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The drug's name is derived from the methylsulfoxy and piperidine functional groups in its chemical structure.

It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.

Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.

It currently appears to be unavailable worldwide.